International Flavors & Fragrances
IFF
$78.47
-0.36%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, operating in the Chemicals - Specialty industry. The company creates proprietary formulations for flavors, fragrances, health, and food ingredients, serving the food, beverage, personal care, and pharmaceutical sectors. The current investor narrative centers on a potential turnaround story, as the company navigates post-merger integration challenges, plans to divest its Food Ingredients business, and seeks to stabilize profitability amidst recent revenue declines and volatile quarterly earnings, with recent news highlighting the stock as an oversold candidate poised for a rebound.…
IFF
International Flavors & Fragrances
$78.47
Related headlines
Investment Opinion: Should I buy IFF Today?
Rating: Hold. The core thesis is that IFF is a high-risk, high-reward turnaround story where the potential for operational recovery is balanced by significant execution risk and weak near-term fundamentals, making it suitable only for patient, risk-tolerant investors at this juncture.
The Hold rating is supported by a valuation that appears to price in much of the bad news, limiting immediate downside. The forward P/E of 14.91 is reasonable for a potential recovery, and the Price-to-Sales ratio of 1.58 sits at historical lows. Positive free cash flow of $256 million and a solid balance sheet (D/E of 0.47) provide financial flexibility. Furthermore, the cautiously optimistic analyst sentiment, with several 'Outperform' ratings, suggests professional money sees a path forward, even if the average target price is not explicitly provided.
The two biggest risks that could invalidate this neutral thesis are 1) a further deceleration in revenue growth or failure to stabilize post-divestiture, and 2) a breakdown in gross margin recovery below 30%. This Hold would upgrade to a Buy if the company demonstrates two consecutive quarters of sequential revenue growth in its core segments and sustains gross margins above 32%. It would downgrade to a Sell if revenue decline accelerates beyond -8% YoY or if the stock breaks decisively below its 52-week low of $59.14. Relative to its own battered history, the stock appears fairly valued for the risks it carries, but it is not yet clearly undervalued enough to warrant an aggressive Buy recommendation.
Sign up to view all
IFF 12-Month Price Forecast
IFF is a 'show me' story where the potential reward of a successful turnaround is counterbalanced by substantial near-term fundamental deterioration. The neutral stance reflects the high degree of binary risk tied to management's execution of its strategic plan. The valuation suggests much of the bad news is priced in, but without clear evidence of operational stabilization, it is premature to be bullish. Confidence is medium due to the wide range of possible outcomes, as indicated by the broad analyst EPS estimates. The stance would upgrade to bullish on confirmation of margin stabilization and a halt in revenue declines in the core post-divestiture business. It would turn bearish if the stock breaks key technical support at $59 or if quarterly losses resume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $102.01 and implied upside of +30.0% versus the current price.
Average Target
$102.01
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$63 - $102
Analyst target range
Analyst coverage for IFF is limited, with only 5 analysts providing estimates, which is low for a company of its market capitalization and suggests it may be under-followed or that there is high uncertainty surrounding its outlook. The consensus sentiment, inferred from recent institutional ratings, appears cautiously optimistic, with firms like Mizuho, Barclays, Wells Fargo, and Citigroup maintaining 'Outperform' or 'Buy' equivalents, and Oppenheimer recently upgrading to 'Outperform'; however, the lack of a published average target price in the data prevents a calculation of implied upside or downside from the current price. The estimated EPS range for the forward period is wide, spanning from $5.09 to $5.52, with an average of $5.23, while the revenue estimate range is $11.57 billion to $12.30 billion. The wide target spreads for both EPS and revenue signal significant uncertainty among analysts regarding the company's near-term earnings power and top-line trajectory, likely tied to execution risks around its restructuring and divestiture plans. The pattern of recent ratings shows stability, with most firms reiterating existing ratings in early 2026, though the limited number of covering analysts means price discovery may be less efficient and the stock could be more susceptible to volatility from individual analyst actions.
Bulls vs Bears: IFF Investment Factors
The evidence presents a classic turnaround investment case with compelling arguments on both sides. The bear case is currently stronger on a near-term fundamental basis, anchored by persistent revenue declines, negative profitability, and severe market underperformance. However, the bull case is gaining traction on a forward-looking valuation and sentiment basis, with the stock trading at historical valuation lows and analysts maintaining a cautiously optimistic stance. The single most important tension in the investment debate is the execution of the corporate restructuring. If management successfully divests the Food Ingredients segment, stabilizes margins in the remaining businesses, and returns to consistent profitability, the historically low valuation provides substantial upside. Conversely, a botched restructuring or failure to halt the revenue slide would validate the bearish fundamentals and could drive the stock back toward its 52-week lows.
Bullish
- Valuation at Historical Lows: The stock's Price-to-Sales ratio of 1.58 is near the bottom of its historical range, having compressed from highs above 12 in 2021. This dramatic de-rating suggests the market has priced in substantial deterioration, potentially limiting further downside and setting a floor for the stock if operations stabilize.
- Analyst Sentiment Cautiously Optimistic: Despite limited coverage, recent institutional ratings from firms like Mizuho, Barclays, and Oppenheimer are 'Outperform' or 'Buy' equivalents. This consensus suggests professional analysts see a path to recovery, with a forward P/E of 14.91 based on estimated EPS of $5.23 indicating a reasonable valuation for a turnaround.
- Strong Balance Sheet & Liquidity: The company maintains a manageable debt-to-equity ratio of 0.47 and a healthy current ratio of 1.42. This financial stability provides a cushion to navigate its restructuring and the planned divestiture of the Food Ingredients business without a liquidity crisis.
- Positive Free Cash Flow Generation: Trailing twelve-month free cash flow is $256 million, providing a FCF yield of approximately 1.5%. This operational cash generation supports the modest dividend and capital expenditures, offering a fundamental underpinning absent from the negative net income figures.
Bearish
- Persistent Revenue Decline: The most recent quarterly revenue of $2.589 billion declined 6.57% year-over-year. This top-line contraction, coupled with the planned divestiture of the largest segment (Food Ingredients at $802M), creates significant uncertainty around the future revenue base and growth trajectory.
- Severe Profitability & Margin Volatility: Profitability is highly inconsistent, with a trailing net margin of -3.43% and diluted EPS of -$0.02. The latest quarter saw gross margin compress to 29.2% from 36.5% in the prior quarter, indicating significant operational pressure and difficulty in achieving stable earnings.
- Massive Underperformance vs. Market: The stock has a relative strength of -38.08 versus the S&P 500 over the past year and is down 9.04% over that period. This severe underperformance, despite a market beta of 1.032, reflects deep-seated investor skepticism and a lack of positive catalysts to drive outperformance.
- High Uncertainty in Analyst Forecasts: Only 5 analysts cover the stock, and their estimated EPS range is wide ($5.09 to $5.52), signaling significant disagreement and uncertainty about near-term earnings. This low coverage and high forecast dispersion increase the risk of price volatility from individual rating changes.
IFF Technical Analysis
The stock is in a state of volatile consolidation following a significant rally and subsequent pullback. Over the past year, the price has declined by 9.04%, yet it has gained 12.45% over the last six months, indicating a partial recovery from deeper lows. Currently trading at $70.81, the price sits approximately 40% above its 52-week low of $59.14 and 16% below its 52-week high of $84.45, positioning it in the lower-middle portion of its annual range, which suggests the stock is neither deeply oversold nor overextended. Recent momentum shows conflicting signals, with a 1.43% gain over the last three months but a 2.43% decline over the past month, indicating a loss of short-term momentum that diverges from the positive six-month trend and may signal a period of consolidation or a pause in the recovery. The stock's beta of 1.032 indicates volatility roughly in line with the broader market, but its severe underperformance is evident with a relative strength of -38.08 versus the S&P 500 over the past year. Key technical levels are clearly defined, with immediate support near the 52-week low of $59.14 and resistance at the 52-week high of $84.45; a decisive break above resistance would signal a resumption of the bullish recovery trend, while a breakdown below support could trigger a retest of multi-year lows. The stock's maximum drawdown of -24.93% over the provided period underscores the significant volatility and risk inherent in its recent price action.
Beta
0.94
0.94x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$59-$84
Price range past year
Annual Return
+2.8%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | +8.2% | +8.6% |
| 3m | +1.9% | +6.7% |
| 6m | +16.4% | +9.8% |
| 1y | +2.8% | +26.6% |
| ytd | +15.3% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
Revenue trends indicate a company in a challenging phase, with the most recent quarterly revenue of $2.589 billion representing a year-over-year decline of 6.57%. Segment data from the latest quarter shows the Food Ingredients business as the largest contributor at $802 million, followed by Scent ($610M), Health & Biosciences ($589M), and Taste ($588M); the planned divestiture of the Food Ingredients segment will fundamentally reshape the company's revenue profile. Profitability is inconsistent and under pressure, with the latest quarter showing a net income of $18 million and a gross margin of 29.2%, which is down from 36.5% in the prior quarter, indicating significant margin compression. The trailing twelve-month net margin is negative at -3.43%, and diluted EPS is -$0.02, reflecting the impact of a substantial net loss of -$1.018 billion in Q1 2025, though the progression to a small profit in Q4 suggests a tentative move towards stabilization. The balance sheet and cash flow situation shows a company with moderate leverage but generating operational cash. The debt-to-equity ratio is a manageable 0.47, and the current ratio is a healthy 1.42, indicating sufficient short-term liquidity. Trailing twelve-month free cash flow is $256 million, providing a FCF yield of approximately 1.5% based on the current market cap, which suggests the company generates enough cash to cover its dividend and modest capital expenditures, though not an overwhelming surplus for aggressive debt reduction or share buybacks.
Quarterly Revenue
$2.6B
2025-12
Revenue YoY Growth
-0.06%
YoY Comparison
Gross Margin
+0.29%
Latest Quarter
Free Cash Flow
$256000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 1.58, while the forward-looking valuation can be inferred from the estimated revenue, yielding a forward PS of approximately 1.46 based on the average analyst revenue estimate of $11.80 billion and the current market cap of $17.25 billion; the slight compression from trailing to forward suggests the market expects only marginal sales growth or improvement. Compared to industry averages, IFF's valuation presents a mixed picture. Its EV/EBITDA of 29.93 is exceptionally high, likely distorted by recent low or negative EBITDA, while its EV/Sales of 2.21 and forward P/E of 14.91 (based on estimated EPS of $5.23) are more standard metrics; however, without a direct industry average provided in the data, a precise premium/discount calculation is not available, though the forward P/E in the mid-teens is not atypical for a stable, large-cap ingredients company. Historically, the stock's own valuation has compressed significantly. The current PS ratio of 1.58 is near the bottom of its historical range observed in the data, which shows figures as high as 12.67 in late 2021; this dramatic de-rating suggests the market has already priced in substantial fundamental deterioration and lowered growth expectations, potentially limiting further multiple contraction and setting a floor for the stock if operations stabilize.
PE
-46.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -651x~339x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on volatile profitability and a shrinking revenue base. The company's trailing net margin is negative at -3.43%, and quarterly gross margin recently compressed from 36.5% to 29.2%, indicating severe operational pressure. The planned divestiture of the Food Ingredients segment, which contributed $802 million last quarter, introduces significant uncertainty and will permanently reduce the company's revenue scale, making future growth more challenging. While free cash flow of $256 million provides a buffer, the negative earnings and wide analyst EPS estimates ($5.09-$5.52) highlight the risk that profitability recovery may be slower or weaker than expected.
Market & Competitive Risks are pronounced given the stock's valuation de-rating and poor relative performance. The stock trades at a forward P/E of 14.91, which is not excessively high, but its EV/EBITDA of 29.93 is distorted and signals past earnings quality issues. The primary market risk is that the stock remains 'dead money' as it has for the past year, underperforming the S&P 500 by 38%. A beta of 1.032 suggests market volatility will be fully transmitted to the stock. Furthermore, as a specialty chemicals company, it faces competitive and pricing pressure in its end markets, which could prolong the margin recovery.
Worst-Case Scenario involves a failure of the turnaround narrative. This would be triggered by a breakdown in the Food Ingredients divestiture process, continued market share loss leading to further revenue declines beyond the current -6.57% YoY trend, and an inability to stabilize gross margins. In this adverse scenario, investor confidence would collapse, leading to multiple compression back to crisis-level valuations. The realistic downside would be a retest and break below the 52-week low of $59.14. From the current price of $70.81, this represents a potential loss of approximately -16.5%. A more severe bear case, factoring in a broader market downturn, could see losses approach -25%, in line with the stock's recent maximum drawdown of -24.93%.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued revenue decline (-6.57% YoY) and volatile, negative profitability (trailing net margin -3.43%) may persist. 2) Execution Risk: The planned divestiture of the large Food Ingredients segment is complex; any delay or failure would cripple the turnaround thesis. 3) Competitive/Market Risk: The stock has severely underperformed the S&P 500 (relative strength -38), indicating a loss of investor favor that may continue. 4) Financial Risk: While the balance sheet is currently stable (D/E 0.47), a prolonged earnings downturn could pressure leverage ratios and the dividend.
The 12-month forecast is highly bifurcated, with a base case target range of $70-$84 (50% probability), a bull case of $84-$95 (30% probability), and a bear case of $59-$68 (20% probability). The base case, which is most likely, assumes the company muddles through its restructuring with stable but unspectacular results, meeting the analyst consensus EPS estimate of $5.23. The key assumption behind this scenario is that management successfully executes the Food Ingredients divestiture without major disruptions. The wide forecast range reflects the high uncertainty and binary nature of the current investment thesis centered on a corporate turnaround.
IFF appears fairly valued relative to its current challenged fundamentals but potentially undervalued on a long-term recovery basis. Its forward P/E of 14.91 is reasonable, but this metric is based on estimated future earnings that are highly uncertain. The more telling metric is the Price-to-Sales ratio of 1.58, which is near the bottom of its own historical range, having fallen from over 12 in 2021. This suggests the market has already priced in substantial deterioration. Compared to stable specialty chemical peers, IFF likely trades at a discount due to its unique operational issues. The current valuation implies the market expects only a slow, uncertain recovery with significant execution risk.
IFF is a speculative buy only for investors with a high risk tolerance and a long-term horizon who believe in management's turnaround plan. The stock trades at a historically low Price-to-Sales multiple of 1.58, suggesting significant upside if operations stabilize. However, it is not a 'good buy' for most investors due to its negative profitability, declining revenue, and severe underperformance versus the market (-38% over the past year). The biggest downside risk is execution failure of the planned divestiture and restructuring. It could become a more compelling buy if the company posts two consecutive quarters of gross margin improvement and sequential revenue growth in its core businesses.
IFF is strictly a long-term investment for patient capital. The turnaround and restructuring process will take multiple quarters, if not years, to play out fully, making the stock unsuitable for short-term trading. Its beta of 1.03 and history of a -25% maximum drawdown indicate high volatility, which is punishing for short-term holders. The modest dividend yield of 2.4% does not provide sufficient income to justify a short-term hold. Investors should have a minimum horizon of 2-3 years to allow management time to execute its plan and for the market to re-rate the stock if fundamentals improve.